Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Adverum Biotechnlgs (ADVM)

Adverum Biotechnlgs (ADVM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 454,436
  • Shares Outstanding, K 64,459
  • Annual Sales, $ 1,610 K
  • Annual Income, $ -72,630 K
  • 60-Month Beta 2.49
  • Price/Sales 273.91
  • Price/Cash Flow N/A
  • Price/Book 2.29

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.27
  • Number of Estimates 4
  • High Estimate -0.24
  • Low Estimate -0.30
  • Prior Year -0.26
  • Growth Rate Est. (year over year) -3.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.96 +42.14%
on 10/10/19
7.16 -1.54%
on 10/17/19
+0.84 (+13.53%)
since 09/17/19
3-Month
4.96 +42.14%
on 10/10/19
15.23 -53.71%
on 07/18/19
-8.28 (-54.01%)
since 07/17/19
52-Week
2.62 +169.08%
on 11/02/18
16.38 -56.97%
on 07/16/19
+2.01 (+39.88%)
since 10/17/18

Most Recent Stories

More News
The Market Timing Secrets No One Talks About - October 14, 2019

Is the ability to time the markets more of a data-driven science or a 'gut - feeling' art?

CLBS : 2.33 (+2.64%)
ADVM : 7.05 (+2.92%)
AAC : 0.40 (+11.11%)
VBIV : 0.54 (+3.73%)
HNGR : 19.97 (+2.73%)
Adverum Biotechnologies Reports Additional Clinical Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting

-- Zero anti-VEGF rescue injections required in the first cohort and durable efficacy with median follow up of 34 weeks --

ADVM : 7.05 (+2.92%)
Kedalion Therapeutics Names New CEO and New Director, Announces Two Promotions, and Will Speak at Ophthalmology Innovation Summit

Kedalion Therapeutics, Inc., a clinical-stage company focused on the development and commercialization of topical ophthalmology therapies based on its proprietary AcuStream(TM) platform, today announced...

ADVM : 7.05 (+2.92%)
AGN : 172.50 (+0.92%)
MDT : 108.51 (+0.01%)
Adverum Biotechnologies Enters Oversold Territory

Adverum Biotechnologies has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

ADVM : 7.05 (+2.92%)
Adverum Biotechnologies to Present Additional Clinical Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy to Treat Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced it will present additional clinical data for...

ADVM : 7.05 (+2.92%)
Adverum Biotechnologies (ADVM) Upgraded to Buy: Here's Why

Adverum Biotechnologies (ADVM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ADVM : 7.05 (+2.92%)
The Keys to Successfully Timing the Markets - September 24, 2019

Is the ability to time the markets more of a data-driven science or a 'gut - feeling' art?

HNGR : 19.97 (+2.73%)
ADVM : 7.05 (+2.92%)
CLBS : 2.33 (+2.64%)
AAC : 0.40 (+11.11%)
VBIV : 0.54 (+3.73%)
Adverum Reports Data From Phase I Wet AMD Study, Stock Down

Adverum Biotechnologies (ADVM) announces data from one cohort of an early-stage study, evaluating its gene therapy candidate, ADVM-022, in patients with wet AMD.

NVS : 87.23 (+0.26%)
REGN : 301.57 (+0.72%)
ADVM : 7.05 (+2.92%)
EDIT : 20.35 (-0.25%)
Adverum Biotechnologies Reports Positive 24-Week Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy to Treat Wet AMD

-- Zero anti-VEGF rescue injections required after one-time intravitreal dose of ADVM-022 --

ADVM : 7.05 (+2.92%)
Adverum Biotechnologies to Host a Conference Call and Webcast to Present 24-week Data from First Cohort of OPTIC Trial of ADVM-022 Intravitreal Injection Gene Therapy to Treat Wet AMD at Retina Society 2019 Annual Meeting

-- Podium presentation of 24-week data from first cohort of the OPTIC trial at Retina Society 2019 Annual Meeting on September 12, 2019 at 7:41 am BST --

ADVM : 7.05 (+2.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Soft.

See More Share

Trade ADVM with:

Business Summary

Adverum Biotechnologies, Inc. is a gene therapy company. The Company discovers and develops novel medicines for patients living with rare diseases. Adverum Biotechnologies Inc, formerly known as Avalanche Biotechnologies Inc., is headquartered in Menlo Park, California.

See More

Key Turning Points

2nd Resistance Point 7.43
1st Resistance Point 7.24
Last Price 7.05
1st Support Level 6.78
2nd Support Level 6.51

See More

52-Week High 16.38
Fibonacci 61.8% 11.13
Fibonacci 50% 9.50
Fibonacci 38.2% 7.88
Last Price 7.05
52-Week Low 2.62

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar